Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells

[1]  M. Korbonits,et al.  Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas , 2015, PloS one.

[2]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[3]  M. Rautiainen,et al.  AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling , 2014, Oncogene.

[4]  I. Germano,et al.  Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells , 2014, Journal of Neuro-Oncology.

[5]  Xiwu Chen,et al.  PPARα activation can help prevent and treat non-small cell lung cancer. , 2014, Cancer research.

[6]  Gong Yang,et al.  Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway , 2014, BMC Cancer.

[7]  V. Esposito,et al.  Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. , 2013, Endocrine-related cancer.

[8]  A. Xuereb-Anastasi,et al.  Aip regulates cAMP signalling and GH secretion in GH3 cells. , 2013, Endocrine-related cancer.

[9]  J. Welsh,et al.  1,25-Dihydroxyvitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARA , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  L. Aaltonen,et al.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. , 2013, Endocrine reviews.

[11]  M. Korbonits,et al.  MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. , 2012, American journal of physiology. Endocrinology and metabolism.

[12]  M. Korbonits,et al.  Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. , 2012, The Journal of clinical endocrinology and metabolism.

[13]  S. Stojilkovic.  Molecular mechanisms of pituitary endocrine cell calcium handling. , 2012, Cell calcium.

[14]  F. Steyn,et al.  Influence of membrane ion channel in pituitary somatotrophs by hypothalamic regulators. , 2012, Cell calcium.

[15]  D. Faulds,et al.  Micronised Fenofibrate , 1997, Drugs.

[16]  M. Zhu,et al.  MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin‐resistant human colon cancer cells , 2011, FEBS letters.

[17]  Shuainan Liu,et al.  Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: Is that a latent disadvantage? , 2011, Journal of Translational Medicine.

[18]  S. Takagi,et al.  PPARα Is Regulated by miR-21 and miR-27b in Human Liver , 2011, Pharmaceutical Research.

[19]  Erik Maronde,et al.  Palmitoylethanolamide Protects Dentate Gyrus Granule Cells via Peroxisome Proliferator-Activated Receptor-Alpha , 2011, Neurotoxicity Research.

[20]  M. Gadelha,et al.  Low Aryl Hydrocarbon Receptor-Interacting Protein Expression Is a Better Marker of Invasiveness in Somatotropinomas than Ki-67 and p53 , 2010, Neuroendocrinology.

[21]  S. Melmed,et al.  Pituitary somatostatin receptor signaling , 2010, Trends in Endocrinology & Metabolism.

[22]  Songtao Yu,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas PPARα: energy combustion, hypolipidemia, inflammation and cancer , 2022 .

[23]  K. Eder,et al.  Fasting Upregulates PPARα Target Genes in Brain and Influences Pituitary Hormone Expression in a PPARα Dependent Manner , 2009, PPAR research.

[24]  I. Blumcke,et al.  No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. , 2009, Clinical neuropathology.

[25]  V. Esposito,et al.  Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. , 2009, Endocrine-related cancer.

[26]  A. Pozzi,et al.  PPARα Ligands as Antitumorigenic and Antiangiogenic Agents , 2008, PPAR research.

[27]  Julian R. E. Davis,et al.  The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[28]  V. Esposito,et al.  Differential expression of neurogenins and NeuroD1 in human pituitary tumours. , 2007, The Journal of endocrinology.

[29]  F. Akın,et al.  The PPAR-Gamma Activator Rosiglitazone Fails to Lower Plasma Growth Hormone and Insulin-Like Growth Factor-1 Levels in Patients with Acromegaly , 2007, Neuroendocrinology.

[30]  B. Estour,et al.  Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. , 2007, The Journal of clinical endocrinology and metabolism.

[31]  D. Keating,et al.  Ghrelin reduces voltage-gated potassium currents in GH3 cells via cyclic GMP pathways , 2005, Endocrine.

[32]  S. Melmed.  Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[33]  K. Shimomura,et al.  Effect of peroxisome proliferator-activated receptor alpha ligand fenofibrate on K(v) channels in the insulin-secreting cell line HIT-T15. , 2006, General physiology and biophysics.

[34]  R. Paschke,et al.  Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene , 2006, Science.

[35]  H. Parkington,et al.  Somatostatin increases voltage-gated K+ currents in GH3 cells through activation of multiple somatostatin receptors. , 2005, Endocrinology.

[36]  B. P. Kota,et al.  An overview on biological mechanisms of PPARs. , 2005, Pharmacological research.

[37]  M. Pawlikowski,et al.  Immunohistochemical detection of PPARgamma receptors in the human pituitary adenomas: correlation with PCNA. , 2005, Folia histochemica et cytobiologica.

[38]  F. Trimarchi,et al.  Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. , 2004, European journal of endocrinology.

[39]  B. Staels,et al.  Different ways to regulate the PPARα stability , 2004 .

[40]  F. Bogazzi,et al.  PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. , 2004, European journal of endocrinology.

[41]  S. Melmed,et al.  PPAR-γ receptor ligands: novel therapy for pituitary adenomas , 2003 .

[42]  J. V. Vanden Heuvel,et al.  Evidence That Peroxisome Proliferator-activated Receptor α Is Complexed with the 90-kDa Heat Shock Protein and the Hepatitis Virus B X-associated Protein 2* , 2003, The Journal of Biological Chemistry.

[43]  N. Macdonald,et al.  PPARα and the regulation of cell division and apoptosis , 2002 .

[44]  W. Baschong,et al.  Control of Autofluorescence of Archival Formaldehyde-fixed, Paraffin-embedded Tissue in Confocal Laser Scanning Microscopy (CLSM) , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[45]  David R. Bell,et al.  Binding of Aryl Hydrocarbon Receptor (AhR) to AhR-interacting Protein , 2000, The Journal of Biological Chemistry.

[46]  A. Aranda,et al.  Activation of the Prolactin Gene by Peroxisome Proliferator-activated Receptor-α Appears to Be DNA Binding-independent* , 1998, The Journal of Biological Chemistry.